Biocept Inc (BIOC)

NASDAQ
0.710
-0.050(-6.58%)
After Hours
0.700
-0.010(-1.408%)
- Real-time Data
  • Volume:
    53,092
  • Day's Range:
    0.710 - 0.760
  • 52 wk Range:
    0.700 - 4.250

BIOC Overview

Prev. Close
0.76
Day's Range
0.71-0.76
Revenue
53.61M
Open
0.73
52 wk Range
0.7-4.25
EPS
-0.979
Volume
53,092
Market Cap
12.16M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
49,170
P/E Ratio
-0.781
Beta
0.719
1-Year Change
-79.84%
Shares Outstanding
17,058,770
Next Earnings Date
Mar 29, 2023
What is your sentiment on Biocept?
or
Market is currently closed. Voting is open during market hours.

Biocept Inc News

Biocept Inc Analysis

Biocept Inc Company Profile

Biocept Inc Company Profile

Employees
179

Biocept, Inc., a molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating cell-free tumor DNA and RNA assays utilizing a standard blood sample. Its cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring to identify resistance mechanisms. The company offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer (NSCLC), gastric cancer, colorectal cancer, prostate cancer, pancreaticobiliary cancer, and ovarian cancer. It also provides cerebrospinal fluid tumor cell and ctDNA and ctRNA testing services to medical oncologists, neuro-oncologists, surgical oncologists, urologists, pulmonologists, pathologists, and other physicians; clinical trial and research services to pharmaceutical companies, biopharmaceutical companies and clinical research organizations; and RT-PCR testing services for COVID-19. The company has a collaboration with CLEARED4 to develop a system for tracking and managing COVID-19 testing requirements and test results for its customers; and with Protean BioDiagnostics, Inc. to research the ability of its Target Selector molecular assay to determine EGFR status in NSCLC patients. Biocept, Inc. was incorporated in 1997 and is headquartered in San Diego, California.

Read More

Analyst Price Target

Average7.500 (+956.34% Upside)
High11
Low4
Price0.71
No. of Analysts2
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Analysts 12-Month Price Target

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellStrong SellStrong Sell
Technical IndicatorsStrong SellStrong SellStrong SellStrong SellStrong Sell
SummaryStrong SellStrong SellStrong SellStrong SellStrong Sell
  • The only way is up
    0
    • Record revenue expected
      0
      • https://www.proactiveinvestors.com/companies/news/971834/biocept-says-demand-for-its-covid-19-rt-pcr-testing-increases-in-2022-amid-omicron-variant-surge-971834.html
        0
        • Biocept dice que la demanda de sus pruebas COVID-19 RT-PCR aumenta en 2022 en medio del aumento de variantes de OmicronBiocept continúa sirviendo a la comunidad con pruebas de alta calidad, habiendo recibido más de 40,000 muestras para pruebas de COVID-19 desde principios de 2022
          0
          • https://www.prnewswire.com/news-releases/quest-diagnostics-now-offers-biocepts-liquid-biopsy-test-for-lung-cancer-expanding-its-menu-of-advanced-cancer-diagnostics-301435081.html
            0
            • https://www.nasdaq.com/articles/7-of-the-best-penny-stocks-to-buy-coming-into-year-end-2021-09-21
              0
              • PROJECTION UNTIL  13$  https://invst.ly/w88nk
                0
                • ..............🚀🚀🚀 $24
                  0
                  • Very good 👍!! Biocept Receives South Korean Patent for Primer-Switch Platform Used to Identify Rare Genetic Mutations, Including Cancer BiomarkersExpands company’s patent portfolio in pursuit of worldwide intellectual property protection for proprietary technology that detects biomarkers in tissue, blood, and cerebrospinal fluid
                    0
                    • Buy now. It's very cheap.
                      0